SCHEMBL5386580

SCHEMBL5386580

CCC(c1ccc(N2CC[C@H](N(C(=O)O)C(C)(C)C)C2=O)c(F)c1)N(C)C

nearest known ligand 0.38

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
F10 P00742 19/20 0.38
NPY2R P49146 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5383367 0.89 F10 (0.36) F10NPY2R
SCHEMBL5371113 0.87 F10 (0.47) F10
SCHEMBL5380004 0.87 F10 (0.47) F10
SCHEMBL5380049 0.86 F10 (0.39) F10
SCHEMBL5386312 0.85 F10 (0.39) F10
SCHEMBL5380531 0.84 F10 (0.38) F10
SCHEMBL5379823 0.84 F10 (0.38) F10
SCHEMBL4508161 0.80 F10 (0.35) F10
SCHEMBL5936099 0.80 F10 (0.47) F10
SCHEMBL4851277 0.79 F10 (0.47) F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235544-B2 for use in conjunction with thrombolytic agents, thus permitting the use of a lower dose of thrombolytic agent; treatment of acute vascular diseases; may have potential in neurogenerative diseases such as Parkinson's and Alzheimer's disease GLAXO GROUP LIMITED (GB) 2007-06-26 US disclosed